DeepMed Research

SWOG

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private, Subsidiary

Established: 1956-01-01

Employees: 101

Market Cap: -

Website: http://www.swog.org

Clinical Trials

Lung-MAP S1400K: c-MET Positive

Phase 2

Completed

Conditions: Recurrent Squamous Cell Lung Carcinoma
Stage IV Squamous Cell Lung Carcinoma AJCC V7

Interventions: Drug: ABBV-399

First Posted Date: 2018-07-02

Last Posted Date: 2021-10-18

Lead Sponsor: SWOG Cancer Research Network

Target Recruit Count: 28

Registration Number: NCT03574753

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

S1702 Isatuximab in Treating Patients With Relapsed or Refractory Primary Amyloidosis

Phase 2

Active, not recruiting

Conditions: Gastrointestinal Hemorrhage
Hepatomegaly
Nausea
Constipation
Primary Systemic Amyloidosis
Recurrent Primary Amyloidosis
Amorphous, Eosinophilic, and Acellular Deposit
Diarrhea
Purpura
Refractory Primary Amyloidosis

Interventions: Biological: Isatuximab
Other: Laboratory Biomarker Analysis

First Posted Date: 2018-04-17

Last Posted Date: 2025-02-27

Lead Sponsor: SWOG Cancer Research Network

Target Recruit Count: 43

Registration Number: NCT03499808

Locations: 🇺🇸
Saint Mary Corwin Medical Center, Pueblo, Colorado, United States
🇺🇸
The Carle Foundation Hospital, Urbana, Illinois, United States
🇺🇸
Genesee Hematology Oncology PC, Flint, Michigan, United States

and more 341 locations

S1501 Carvedilol in Preventing Cardiac Toxicity in Patients With Metastatic HER-2-Positive Breast Cancer

Phase 3

Recruiting

Conditions: Stage IV Breast Cancer AJCC v6 and v7
Recurrent Breast Carcinoma
HER2/Neu Positive
Metastatic Malignant Neoplasm in the Brain
Cardiotoxicity

Interventions: Other: Laboratory Biomarker Analysis
Drug: Carvedilol
Other: Patient Observation

First Posted Date: 2018-02-01

Last Posted Date: 2025-05-15

Lead Sponsor: SWOG Cancer Research Network

Target Recruit Count: 817

Registration Number: NCT03418961

Locations: 🇺🇸
USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸
John H Stroger Jr Hospital of Cook County, Chicago, Illinois, United States
🇺🇸
Cleveland Clinic Cancer Center/Fairview Hospital, Cleveland, Ohio, United States

and more 587 locations

Lung-MAP: Talazoparib in Treating Patients With HRRD Positive Recurrent Stage IV Squamous Cell Lung Cancer

Phase 2

Completed

Conditions: BARD1 Gene Mutation
FANCM Gene Mutation
Recurrent Squamous Cell Lung Carcinoma
ATR Gene Mutation
BRCA2 Gene Mutation
FANCC Gene Mutation
FANCF Gene Mutation
RAD54L Gene Mutation
CHEK2 Gene Mutation
FANCD2 Gene Mutation

Interventions: Other: Laboratory Biomarker Analysis
Other: Pharmacological Study
Drug: Talazoparib

First Posted Date: 2017-12-19

Last Posted Date: 2021-06-23

Lead Sponsor: SWOG Cancer Research Network

Target Recruit Count: 51

Registration Number: NCT03377556

Locations: 🇺🇸
Cancer Center of Kansas-Independence, Independence, Kansas, United States
🇺🇸
Rush - Copley Medical Center, Aurora, Illinois, United States
🇺🇸
Mercy Hospital Joplin, Joplin, Missouri, United States

and more 1149 locations

Durvalumab and Tremelimumab in Treating Patients With Recurrent Stage IV Lung Cancer

Phase 2

Completed

Conditions: Stage IV Squamous Cell Lung Carcinoma AJCC v7
Recurrent Squamous Cell Lung Carcinoma

Interventions: Biological: Durvalumab
Other: Laboratory Biomarker Analysis
Biological: Tremelimumab

First Posted Date: 2017-12-14

Last Posted Date: 2023-06-09

Lead Sponsor: SWOG Cancer Research Network

Target Recruit Count: 67

Registration Number: NCT03373760

Locations: 🇺🇸
JCHC McCreery Cancer Center, Fairfield, Iowa, United States
🇺🇸
Ottumwa Regional Health Center, Ottumwa, Iowa, United States
🇺🇸
Covenant Medical Center, Waterloo, Iowa, United States

and more 1012 locations

S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery

Phase 2

Active, not recruiting

Conditions: Stage III Colon Cancer AJCC v7
Colon Adenocarcinoma
Recurrent Rectal Carcinoma
Stage IIIB Rectal Cancer AJCC v7
Stage IVA Colon Cancer AJCC v7
Stage IVB Colon Cancer AJCC v7
Rectal Adenocarcinoma
Recurrent Colon Carcinoma
Stage IIIB Colon Cancer AJCC v7
Stage IV Colon Cancer AJCC v7

Interventions: Other: Laboratory Biomarker Analysis
Biological: Cetuximab
Biological: Pertuzumab
Drug: Irinotecan Hydrochloride
Biological: Trastuzumab
Device: HER-2 testing

First Posted Date: 2017-12-07

Last Posted Date: 2025-01-14

Lead Sponsor: SWOG Cancer Research Network

Target Recruit Count: 240

Registration Number: NCT03365882

Locations: 🇺🇸
North Star Lodge Cancer Center at Yakima Valley Memorial Hospital, Yakima, Washington, United States
🇺🇸
West Virginia University Healthcare, Morgantown, West Virginia, United States
🇺🇸
Cancer Center of Western Wisconsin, New Richmond, Wisconsin, United States

and more 793 locations

S1602: Different Strains of BCG With or Without Vaccine in High Grade Non- Muscle Invasive Bladder Cancer

Phase 3

Active, not recruiting

Conditions: Stage 0is Bladder Urothelial Carcinoma
Stage 0 Bladder Urothelial Carcinoma
Stage I Bladder Urothelial Carcinoma

Interventions: Biological: BCG Solution
Biological: BCG Tokyo-172 Strain Solution
Other: Laboratory Biomarker Analysis
Biological: BCG Tokyo-172 Strain Vaccine

First Posted Date: 2017-03-27

Last Posted Date: 2025-04-02

Lead Sponsor: SWOG Cancer Research Network

Target Recruit Count: 1000

Registration Number: NCT03091660

Locations: 🇺🇸
Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States
🇺🇸
Marshfield Clinic-Wausau Center, Wausau, Wisconsin, United States
🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

and more 171 locations

S9005 Mifepristone in Meningioma

Phase 3

Completed

Conditions: Meningioma

Interventions: Other: Placebo
Drug: Mifepristone

First Posted Date: 2017-01-10

Last Posted Date: 2019-12-23

Lead Sponsor: SWOG Cancer Research Network

Target Recruit Count: 193

Registration Number: NCT03015701

Lung-MAP: AZD4547 as Second-Line Therapy in Treating FGFR Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer

Phase 2

Completed

Conditions: FGFR2 Gene Amplification
FGFR3 Gene Amplification
FGFR2 Gene Mutation
Stage IV Squamous Cell Lung Carcinoma AJCC v7
FGFR1 Gene Mutation
FGFR1 Gene Amplification
Recurrent Squamous Cell Lung Carcinoma
FGFR3 Gene Mutation

Interventions: Drug: FGFR Inhibitor AZD4547
Drug: Docetaxel
Other: Laboratory Biomarker Analysis

First Posted Date: 2016-11-16

Last Posted Date: 2021-05-27

Lead Sponsor: SWOG Cancer Research Network

Target Recruit Count: 43

Registration Number: NCT02965378

Locations: 🇺🇸
Kaiser Permanente-Redwood City, Redwood City, California, United States
🇺🇸
AIS Cancer Center at San Joaquin Community Hospital, Bakersfield, California, United States
🇺🇸
City of Hope Antelope Valley, Lancaster, California, United States

and more 1073 locations

Lung-MAP: Rilotumumab and Erlotinib Hydrochloride or Erlotinib Hydrochloride Alone as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches

Phase 2

Terminated

Conditions: Stage IV Squamous Cell Lung Carcinoma AJCC v7
Recurrent Squamous Cell Lung Carcinoma
MET Positive

Interventions: Drug: Erlotinib Hydrochloride
Other: Laboratory Biomarker Analysis
Biological: Rilotumumab

First Posted Date: 2016-10-06

Last Posted Date: 2020-03-19

Lead Sponsor: SWOG Cancer Research Network

Target Recruit Count: 9

Registration Number: NCT02926638

Locations: 🇺🇸
Grant Medical Center, Columbus, Ohio, United States
🇺🇸
MedStar Union Memorial Hospital, Baltimore, Maryland, United States
🇺🇸
Sky Ridge Medical Center, Lone Tree, Colorado, United States

and more 617 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy